Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
出版年份 2022 全文链接
标题
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 19, Issue 5, Pages 342-355
出版商
Springer Science and Business Media LLC
发表日期
2022-03-23
DOI
10.1038/s41571-022-00607-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
- (2021) Stephan Kadauke et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute Lymphoblastic Leukemia: A Population‐ based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results ( SEER ) Database, 1980‐2017
- (2021) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children—a novel health disparity
- (2021) Gordana Raca et al. LEUKEMIA
- Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
- (2021) Karlo Perica et al. LEUKEMIA
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation
- (2021) Shuangyou Liu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
- (2021) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Olalekan O. Oluwole et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
- (2021) Li-Chung Tsao et al. CANCER RESEARCH
- Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
- (2021) Belén Blanco et al. CLINICAL CANCER RESEARCH
- Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
- (2021) Bijal D. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- (2021) Bijal D Shah et al. LANCET
- A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
- (2021) Kathryn M. Cappell et al. Nature Reviews Clinical Oncology
- Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
- (2021) Nora Liebers et al. Blood Advances
- Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Max S. Topp et al. BRITISH JOURNAL OF HAEMATOLOGY
- Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- CAR T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloleucel, a Single Center Experience
- (2020) Nathan Denlinger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
- (2020) Paulina Horvei et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
- (2020) N. Nora Bennani et al. BLOOD
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
- (2020) Jeremy S. Abramson et al. BLOOD
- Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
- (2020) Michael D. Jain et al. BLOOD
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- CAR T-cell product performance in haematological malignancies before and after marketing authorisation
- (2020) Magdi Elsallab et al. LANCET ONCOLOGY
- Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy
- (2020) Diane Libert et al. LEUKEMIA
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma
- (2020) Christopher M. Wright et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
- (2020) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Commercial anti‐CD19 CAR T Cell Therapy for Patients with Relapsed/Refractory Aggressive B Cell Lymphoma in a European center
- (2020) Pierre Sesques et al. AMERICAN JOURNAL OF HEMATOLOGY
- How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population
- (2020) Stephen P. Hunger et al. BLOOD
- Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
- (2020) Bachar Samra et al. Journal of Hematology & Oncology
- Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas
- (2020) P. Connor Johnson et al. LEUKEMIA & LYMPHOMA
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
- (2020) Chelsea C. Pinnix et al. Blood Advances
- Bilateral retinal detachment after chimeric antigen receptor T-cell therapy
- (2020) Christopher C. Denton et al. Blood Advances
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
- (2020) Kathryn M. Cappell et al. JOURNAL OF CLINICAL ONCOLOGY
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy
- (2020) Bicky Thapa et al. Blood Advances
- Use of cardiac radiation therapy as bridging therapy to CAR‐T for relapsed pediatric B‐cell acute lymphoblastic leukemia
- (2020) Cesar P. Marquez et al. PEDIATRIC BLOOD & CANCER
- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
- (2019) Emma J.M. Grigor et al. TRANSFUSION MEDICINE REVIEWS
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells
- (2019) Philipp Karschnia et al. BLOOD
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues
- (2019) Jérémie Gaudichon et al. BLOOD REVIEWS
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
- (2019) Ankit J. Kansagra et al. BONE MARROW TRANSPLANTATION
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- (2019) Jing Pan et al. LEUKEMIA
- Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma
- (2019) Matthew J. Frigault et al. BLOOD
- Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
- (2019) Sandhya R. Panch et al. MOLECULAR THERAPY
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
- (2019) Yaqing Cao et al. Frontiers in Oncology
- A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
- (2019) Sunita Dwivedy Nasta et al. BLOOD
- CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial
- (2019) Ann-Marie E Bröske et al. BLOOD
- Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma
- (2019) Caspian Oliai et al. BLOOD
- Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel
- (2019) Ajeet Gajra et al. BLOOD
- Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience
- (2019) Jérôme Paillassa et al. BLOOD
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
- (2019) Charalambos Andreadis et al. BLOOD
- A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
- (2019) Peter A. Riedell et al. BLOOD
- Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- (2019) Ibrahim Yakoub-Agha et al. HAEMATOLOGICA
- Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma
- (2019) Kirk E. Cahill et al. LEUKEMIA & LYMPHOMA
- Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
- (2019) Rebecca A. Gardner et al. BLOOD
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
- (2018) Inmaculada Hernandez et al. JAMA Oncology
- Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
- (2018) Elad Jacoby et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- (2018) Kris M. Mahadeo et al. Nature Reviews Clinical Oncology
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- (2018) Reith R Sarkar et al. JNCI-Journal of the National Cancer Institute
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous lymphapheresis for the production of chimeric antigen receptor T cells
- (2017) Elizabeth S. Allen et al. TRANSFUSION
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- CAR-T Cell Therapy for Lymphoma
- (2016) Carlos A. Ramos et al. Annual Review of Medicine
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- CAR-T Cell Therapies From the Transfusion Medicine Perspective
- (2016) Andrew Fesnak et al. TRANSFUSION MEDICINE REVIEWS
- The Cell Killing Mechanisms of Hydroxyurea
- (2016) Amanpreet Singh et al. Genes
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
- (2015) Ching-Hon Pui et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Opportunities and challenges of radiotherapy for treating cancer
- (2015) Dörthe Schaue et al. Nature Reviews Clinical Oncology
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia
- (2014) Kjeld Schmiegelow et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- Diffuse large B-cell lymphoma
- (2013) Maurizio Martelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Asparaginases
- (2011) Vassilios I. Avramis JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
- (2009) Claudia Wrzesinski et al. JOURNAL OF IMMUNOTHERAPY
- CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
- (2009) A Takeshita et al. LEUKEMIA
- Cyclophosphamide and cancer: golden anniversary
- (2009) Ashkan Emadi et al. Nature Reviews Clinical Oncology
- Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells
- (2008) J. Cai et al. CANCER RESEARCH
- Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
- (2008) H. Konig et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started